TrialCancer control : journal of the Moffitt Cancer Center

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.

Jiaqi Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.